Your browser doesn't support javascript.
Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.
Zhao, Hong; Zhou, Aiping; Zhou, Jianguo; Bi, Xinyu; Yan, Shida; Jin, Jing; Wei, Wenqiang; Li, Muxing; Gong, Caifeng; Chen, Qichen; Luo, Zhiwen; Li, Ning; Mao, Rui; Chen, Xiao; Chen, Bo; Zheng, Rongshou; Zhao, Jianjun; Han, Yue; Li, Zhiyu; Che, Xu; Tang, Yuan; Sun, Yongkun; Huang, Zhen; Zhang, Yefan; Wang, Xiaoying; Zhang, Yubao; Lu, Zhenhui; Dang, Xiaowei; Song, Tianqiang; Liu, Chang; Yue, Ping; Yan, Dong; Yue, Aimin; Zhang, Rui; Luo, Suxia; Tan, Jing; Zhang, Xuewen; Bai, Xueli; Zhang, Xuejun; He, Mingyan; Xie, Yujun; Wang, Wenling; Yang, Po; Yang, Yijun; Zhang, Yamin; Li, Qingdong; Peng, Tao; Wang, Zusen; Chen, Yajin; Shang, Changzhen.
  • Zhao H; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Key Laboratory of Gene Editing Screening and R&D of Digestive System Tumor Drugs, Chines
  • Zhou A; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhou J; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Bi X; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Key Laboratory of Gene Editing Screening and R&D of Digestive System Tumor Drugs, Chines
  • Yan S; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Jin J; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Wei W; Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Li M; Department of General Surgery, Peking University Third Hospital, Beijing, China.
  • Gong C; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Chen Q; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Luo Z; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Li N; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Mao R; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Chen X; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Chen B; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zheng R; Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhao J; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Han Y; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Li Z; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Che X; Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center/National
  • Tang Y; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Sun Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Huang Z; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhang Y; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Wang X; Department of Liver Surgery & Liver Transplant Center, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Zhang Y; Department of Hepatobiliary and Pancreatic Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
  • Lu Z; Departments of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China.
  • Dang X; Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Song T; Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
  • Liu C; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Yue P; Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China.
  • Yan D; Department of Hepatopancreatobiliary Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China.
  • Yue A; Department of Surgical Oncology, Xinxiang Central Hospital, Xinxiang, China.
  • Zhang R; Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
  • Luo S; Henan Cancer Hospital, Zhengzhou, China.
  • Tan J; Yan'an Affiliated Hospital of Kunming Medical University, Kunming, China.
  • Zhang X; Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun, China.
  • Bai X; Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang Clinical Research Cneter of Hepatobiliary and Pancreatic Diseases, Hangzhou, China.
  • Zhang X; Department of Intervention, Inner Mongolia People's Hospital, Hohhot, China.
  • He M; Department of the Third Abdominal Surgery, Gansu Provincial Cancer Hospital, Lanzhou, China.
  • Xie Y; Department of Intervention Ultrasound, Ningxia People's Hospital, Yinchuan, China.
  • Wang W; Department of Oncology, The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China.
  • Yang P; Department of Interventional & Vascular Therapy, The Fourth Hospital of Harbin Medical University, Harbin, China.
  • Yang Y; Department of Hepatobiliary Surgery, Haikou Municipal Hospital, Haikou, China.
  • Zhang Y; Department of Hepatobiliary Surgery, Tianjin First Center Hospital, Tianjin, China.
  • Li Q; Vascular and Interventional Department, Chongqing University Cancer Hospital, Chongqing, China.
  • Peng T; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Wang Z; Department of Hepatobiliary Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Chen Y; Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
  • Shang C; Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
HPB (Oxford) ; 24(3): 342-352, 2022 03.
Article in English | MEDLINE | ID: covidwho-1360060
ABSTRACT

BACKGROUND:

This study aimed to investigate the work status of clinicians in China and their management strategy alteration for patients with hepatocellular carcinoma (HCC) during the COVID-19 pandemic.

METHODS:

A nationwide online questionnaire survey was conducted in 42 class-A tertiary hospitals across China. Experienced clinicians of HCC-related specialties responded with their work status and management suggestions for HCC patients during the pandemic.

RESULTS:

716 doctors responded effectively with a response rate of 60.1%, and 664 were included in the final analysis. Overall, 51.4% (341/664) of clinicians reported more than a 60% reduction of the regular workload and surgeons declared the highest proportion of workload reduction. 92.5% (614/664) of the respondents have been using online medical consultation to substitute for the "face-to-face" visits. Adaptive adjustment for the treatment strategy for HCC was made, including the recommendations of noninvasive and minimally invasive treatments such as transcatheter arterial chemoembolization for early and intermediate stage. Targeted therapy has been the mainstay for advanced stage and also as a bridge therapy for resectable HCC.

DISCUSSION:

During the COVID-19 pandemic, online medical consultation is recommended to avoid social contact. Targeted therapy as a bridge therapy is recommended for resectable HCC considering the possibility of delayed surgery.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Chemoembolization, Therapeutic / Carcinoma, Hepatocellular / COVID-19 / Liver Neoplasms Type of study: Diagnostic study / Observational study / Qualitative research / Randomized controlled trials Limits: Humans Language: English Journal: HPB (Oxford) Journal subject: Gastroenterology Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Chemoembolization, Therapeutic / Carcinoma, Hepatocellular / COVID-19 / Liver Neoplasms Type of study: Diagnostic study / Observational study / Qualitative research / Randomized controlled trials Limits: Humans Language: English Journal: HPB (Oxford) Journal subject: Gastroenterology Year: 2022 Document Type: Article